Back to the journal

Peptides

Six peptides, and the form that counts

Six peptides, and the form that counts

5 min read

Short answer. The policy's Appendix A names six peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. Appendix B then limits each one to a named form and named routes [2]. As of Oct 29, 2026.

The notice says HHS does not intend to take enforcement action when a covered compounder uses a peptide bulk drug substance in Appendix A [1]. The policy says the substance also has to match the identity and the route limits in Appendix B [2]. Identity includes the amino acid sequence, chemical structure, molecular weight, and molecular formula [2].

The table in the policy

Peptide

Form the policy names

Routes the policy names

BPC-157

Acetate

Under the skin, into muscle, oral, topical

TB-500

Acetate

Under the skin or into muscle

Epitalon

Acetate

Under the skin or into muscle, in intermittent courses

Semax

Free base

Intranasal

KPV

Acetate

Topical and oral

MOTS-c

Acetate

Under the skin or into muscle

Source: Appendix B of the policy [2]. "Intermittent courses" is the policy's phrase for epitalon. The policy does not publish a dose.

What a close name does not do

A free-base version is not the acetate the policy names, except for semax, where the policy names the free base [2]. A route that is not in the row is not a route this discretion describes. A blend of two names is outside the single-ingredient condition [2].

Category 2 placement until April 22, 2026 did not change the 503A status of these substances. The policy says that for each of them. It also says FDA's drug center recommended against listing them, and the Pharmacy Compounding Advisory Committee voted to include them [2]. A vote is not the bulks list. The notice says the list is still in rulemaking [1].

Each peptide has its own note in this batch. Start with the hub if you want the whole announcement in one place: HHS and 6 peptides: what changed.

FAQ

Are these six FDA-approved now? No. The notice says compounded drugs are not FDA-approved [1].

Does any similar peptide get the same treatment? Only if it is one of these six, in the form and route Appendix B names [2].

Sources

  1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

  2. HHS policy, Appendices A and B. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Sommar Club does not prescribe or sell these six. Education only. Not medical or legal advice. As of Oct 29, 2026.

Three minutes tonight.

Answer a few questions. Hear back from a clinician, usually within a day.

See if you qualifyFree online visit. Pay nothing unless approved.
Sommar Club NAD+ editorial product conceptNAD+
Sommar Club GLP-1 CARE editorial product conceptGLP-1 CARE
Sommar Club SERMORELIN editorial product conceptSERMORELIN